PH12015500823A1 - Modified release formulations for oprozomib - Google Patents

Modified release formulations for oprozomib

Info

Publication number: PH12015500823A1
Authority: PH; Philippines
Prior art keywords: oprozomib; modified release; release formulations; release pharmaceutical; formulations
Prior art date: 2012-10-24

Application number

PH12015500823A

Other languages

English (en)

Inventor

Jumaa Mouhannad

Muchamuel Tony

Bejugam Naveen

Wong Hansen

Christopher J Kirk

Manek Rahul Vishram

Sharma Sanjeev

Original Assignee

Onyx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-24

Filing date

2015-04-15

Publication date

2015-06-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50485877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015500823(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-15 Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc

2015-06-22 Publication of PH12015500823A1 publication Critical patent/PH12015500823A1/en

Links

108010064641 ONX 0912 Proteins 0.000 title abstract 2
238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title abstract 2
229950005750 oprozomib Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
-1 e.g. Substances 0.000 abstract 1
238000013265 extended release Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000007909 solid dosage form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Hematology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Tropical Medicine & Parasitology (AREA)
Otolaryngology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PH12015500823A 2012-10-24 2015-04-15 Modified release formulations for oprozomib PH12015500823A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261717975P	2012-10-24	2012-10-24
US201261721244P	2012-11-01	2012-11-01
US201361793087P	2013-03-15	2013-03-15
PCT/US2013/066679 WO2014066681A1 (en)	2012-10-24	2013-10-24	Modified release formulations for oprozomib

Publications (1)

Publication Number	Publication Date
PH12015500823A1 true PH12015500823A1 (en)	2015-06-22

Family

ID=50485877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH12015500823A PH12015500823A1 (en)	2012-10-24	2015-04-15	Modified release formulations for oprozomib

Country Status (24)

Country	Link
US (2)	US9295708B2 (2)
EP (1)	EP2912025A4 (2)
JP (1)	JP6505604B2 (2)
KR (1)	KR20150070406A (2)
CN (1)	CN104968650A (2)
AP (1)	AP3681A (2)
AR (1)	AR093126A1 (2)
AU (1)	AU2013334258A1 (2)
BR (1)	BR112015008572A2 (2)
CA (1)	CA2888039A1 (2)
CL (1)	CL2015001085A1 (2)
CR (1)	CR20150266A (2)
EA (1)	EA201590797A1 (2)
HK (2)	HK1208222A1 (2)
IL (1)	IL238244A0 (2)
IN (1)	IN2015DN03921A (2)
MX (1)	MX2015005069A (2)
PE (1)	PE20151051A1 (2)
PH (1)	PH12015500823A1 (2)
SG (1)	SG11201502849XA (2)
TN (1)	TN2015000135A1 (2)
TW (1)	TW201422255A (2)
UY (1)	UY35091A (2)
WO (1)	WO2014066681A1 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US10653699B2 (en)	2015-06-19	2020-05-19	Biotie Therapies, Inc.	Controlled-release tozadenant formulations
CN105949279A (zh) *	2016-04-27	2016-09-21	浙江大学	蛋白酶体抑制剂Oprozomib及其类似物的制备方法
WO2018005781A1 (en)	2016-06-29	2018-01-04	Kezar Life Sciences	Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
US20180078532A1 (en) *	2016-09-21	2018-03-22	Amgen Inc.	Immediate release formulations for oprozomib
WO2018112078A1 (en)	2016-12-14	2018-06-21	Amgen Inc.	Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
BR112020005079A2 (pt)	2017-09-14	2020-09-15	Glaxosmithkline Intellectual Property Development Limited	tratamento de combinação para câncer
CN110357940A (zh) *	2019-08-02	2019-10-22	苏州艾和医药科技有限公司	奥普佐米合成工艺研究
US20250295771A1 (en)	2022-05-11	2025-09-25	Celgene Corporation	Methods and uses related to t cell therapy and production of same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5126145A (en) *	1989-04-13	1992-06-30	Upsher Smith Laboratories Inc	Controlled release tablet containing water soluble medicament
JPH06199657A (ja) *	1992-12-10	1994-07-19	Sumitomo Pharmaceut Co Ltd	徐放性製剤
WO1998010779A1 (en)	1996-09-13	1998-03-19	New York University	Method for treating parasitic diseases with proteasome inhibitors
JP4748839B2 (ja) *	1999-03-25	2011-08-17	大塚製薬株式会社	シロスタゾール製剤
EA011451B1 (ru) *	2001-02-12	2009-04-28	Уайт	Новая соль сукцинат о-десметилвенлафаксина
US8119154B2 (en) *	2004-04-30	2012-02-21	Allergan, Inc.	Sustained release intraocular implants and related methods
EP2623113B1 (en) *	2005-11-09	2017-05-31	Onyx Therapeutics, Inc.	Compound for enzyme inhibition
US20100172988A1 (en) *	2006-01-10	2010-07-08	Kissei Pharmaceutical Co., Ltd.	Sustained release preparation and method for production thereof
WO2008140782A2 (en)	2007-05-10	2008-11-20	Proteolix, Inc.	Compounds for enzyme inhibition
CA2701778C (en) *	2007-10-04	2018-09-11	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AR075899A1 (es) *	2009-03-20	2011-05-04	Onyx Therapeutics Inc	Tripeptidos epoxicetonas cristalinos inhibidores de proteasa

2013
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en not_active Ceased
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2912025A4 (en)	2016-06-08
WO2014066681A1 (en)	2014-05-01
JP2015535255A (ja)	2015-12-10
TN2015000135A1 (en)	2016-10-03
US9295708B2 (en)	2016-03-29
EA201590797A1 (ru)	2016-02-29
PE20151051A1 (es)	2015-08-03
TW201422255A (zh)	2014-06-16
CN104968650A (zh)	2015-10-07
SG11201502849XA (en)	2015-05-28
BR112015008572A2 (pt)	2017-07-04
KR20150070406A (ko)	2015-06-24
EP2912025A1 (en)	2015-09-02
CA2888039A1 (en)	2014-05-01
AR093126A1 (es)	2015-05-20
JP6505604B2 (ja)	2019-04-24
AU2013334258A1 (en)	2015-04-30
CR20150266A (es)	2015-08-14
MX2015005069A (es)	2015-07-17
IN2015DN03921A (2)	2015-10-02
IL238244A0 (en)	2015-06-30
UY35091A (es)	2014-05-30
HK1215709A1 (zh)	2016-09-09
US20140113855A1 (en)	2014-04-24
US20160213610A1 (en)	2016-07-28
AP2015008387A0 (en)	2015-04-30
AP3681A (en)	2016-04-19
HK1208222A1 (en)	2016-02-26
CL2015001085A1 (es)	2015-08-28

Publication	Publication Date	Title
IN2015DN03921A (2)	2015-10-02
SG10201810985XA (en)	2019-01-30	Tofacitinib oral sustained release dosage forms
EA201200937A1 (ru)	2013-02-28	Твердая лекарственная форма тикагрелора
MX354210B (es)	2018-02-16	Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
IN2012DN06720A (2)	2015-10-23
MY165149A (en)	2018-02-28	Use of binders for manufacturing storage stable formulations
MX2013001677A (es)	2013-07-22	Formulaciones estables de linaclotida.
MY157673A (en)	2016-07-15	Pharmaceutical compositions comprising hydromorphone and naloxone
PH12012502083A1 (en)	2017-07-26	Manufacturing of active-free granules and tablets comprising the same
PH12012502082A1 (en)	2022-10-05	Combination of active loaded granules with additional actives
TN2011000651A1 (en)	2013-05-24	Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
MX2016006087A (es)	2016-08-12	Formulaciones de desintegracion rapida y metodos de uso.
EA201991286A1 (ru)	2019-10-31	Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA201590732A1 (ru)	2016-01-29	Диспергируемая таблетка
PH12016502540B1 (en)	2022-07-20	Pharmaceutical dosage forms
ZA201500411B (en)	2016-01-27	Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
EA201491477A1 (ru)	2015-02-27	Фармацевтические составы, содержащие флупиртин
MY159675A (en)	2017-01-13	Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
IN2015MU00907A (2)	2015-04-24
ES2422657A1 (es)	2013-09-12	Composición farmacéutica sólida de cilostazol
WO2014064711A3 (en)	2014-06-19	Methods of administering raltegravir and raltegravir compositions
WO2011107922A3 (en)	2012-04-26	Extended release composition of milnacipran
SA515360445B1 (ar)	2017-08-17	قرص قابل للتشتيت